Margetuximab
Margetuximab Basic information
- Product Name:
- Margetuximab
- Synonyms:
-
- Margetuximab
- Research Grade Margetuximab(DHC09604)
- Margetuximab (anti-HER2)
- Research Grade Margetuximab
- CAS:
- 1350624-75-7
- MW:
- 0
- Mol File:
- Mol File
Margetuximab Chemical Properties
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
Margetuximab Usage And Synthesis
Uses
Margetuximab (MGAH22) is a chimeric anti-HER2 monoclonal antibody optimized Fc domain, with an EC50 value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer[1].
in vivo
Margetuximab (2-4 mg/kg; IP 5 or 6 times at weekly) can firstly and significantly reduces the tumor size at day 30 - 37 in mice model[1].
Margetuximab (15-150 mg/kg; IV; 6 weekly) exhibits well tolerated in cynomolgus monkeys, decreases NK cells by an average of 51%, and induces IL-6 release[1].
Margetuximab (50 mg/kg; IV; single dosage) exhibits favorable safety profile[1].
Pharmacokinetic Parameters of Margetuximab in cynomolgus monkeys[1].
| Male, IV (50 mg/kg) | Female, IV (50 mg/kg) | |
| Cmax (mg/mL) | 1.62 ± 0.10 | 1.70 ± 0.14 |
| AUC0-￥ (mg·hour/mL) | 294.1 ± 53.2 | 314.2 ± 31.3 |
| T1/2β (days) | 9.3 ± 1.8 | 9.7 ± 1.1 |
| Clearance (mL/hour) | 0.43 ± 0.07 | 0.40 ± 0.04 |
| VSS (mL) | 132 ± 2 | 127 ± 8 |
References
[1] Nordstrom JL, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011;13(6):R123. doi:10.1186/bcr3069
MargetuximabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com